Ligand Pharmaceuticals

Traded on the St. Petersburg Stock Exchange
Ligand Pharmaceuticals is a biopharmaceutical company. Initially focused on developing its own drugs, a period of turbulence in the early 2000s culminated a change in focus to the acquisition of existing drugs and forming partnerships to develop them further.
Ligand Pharmaceuticals stock price chart
vol.
change
P/E adj.
Net profit (adj.)
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Ligand Pharmaceuticals balance sheet

Report period2018 2019 2020 2021 2022Q1 23
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Ligand Pharmaceuticals cash flows

Report period2017 2018 2019 2020 2021 2022
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
Adjusted Earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS
Adjusted EPS

Ligand Pharmaceuticals multipliers

Report period2018 2019 2020 2021 2022Q1 23 TTM
P/E
P/E adj.
E/P
E adj./P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Ligand Pharmaceuticals profitability

Report period2018 2019 2020 2021 2022Q1 23 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Ligand Pharmaceuticals assets
Ligand Pharmaceuticals cash flows

Ligand Pharmaceuticals shares

TickerNameTypeNominal valueISINPrice
LGND:USLigand Pharmaceuticals, Inc.Common share-US53220K5048$107
Ligand Pharmaceuticals news
05.05.2022
Ligand Pharmaceuticals' GAAP loss for 3 months of 2022 was $15.385 million, compared to a profit of $18.106 million in the previous year. Revenue decreased by 17.1% to $45.693 million from $55.15 million a year earlier.
Source: {source} pictogram investor.ligand.com
Pictogram next
24.03.2022
OmniAb, owned by Ligand Pharmaceuticals, has entered into a merger agreement with SPAC Avista Public Acquisition Corp. II. Avista now has $266 million in its escrow account. Ligand shareholders will own 75% to 84% of the combined company, and its shares will trade on the Nasdaq under the ticker symbol OABI.
Source: {source} pictogram investor.ligand.com
Pictogram next
18.02.2022
Ligand Pharmaceuticals' GAAP net income for 2021 was $57.586 million, compared to a loss of $2.985 million in the previous year. Revenue increased 48.7% to $277.133 million from $186.419 million a year earlier.
Source: {source} pictogram investor.ligand.com
Pictogram next
10.11.2021
Ligand Pharmaceuticals' GAAP net income for 9M 2021 was $62.554 million, compared to a loss of $8.746 million in the previous year. Revenue increased 75.8% to $204.66 million from $116.429 million a year earlier.
Source: {source} pictogram investor.ligand.com
Pictogram next
All Ligand Pharmaceuticals news
General information
Company nameLigand Pharmaceuticals
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business address3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121 858-550-7500
Mailing address3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121
Websitewww.ligand.com
Information disclosurewww.sec.gov